DrugPatentWatch Database Preview
Drugs in Development Information for GC4419
» See Plans and Pricing
What is the development status for investigational drug GC4419?
GC4419 is an investigational drug.
There have been 12 clinical trials for GC4419.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 3rd 2018.
The most common disease conditions in clinical trials are Head and Neck Neoplasms, Stomatitis, and Mucositis. The leading clinical trial sponsors are Galera Therapeutics, Inc., INC Research, and INC Research Australia Pty Ltd.
There are three US patents protecting this investigational drug and seventeen international patents.
Summary for GC4419
| US Patents | 3 |
| International Patents | 17 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2018-10-03) |
| Vendors | 0 |
Recent Clinical Trials for GC4419
| Title | Sponsor | Phase |
|---|---|---|
| A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 | Galera Therapeutics, Inc. | Phase 2 |
| Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer | Galera Therapeutics, Inc. | Phase 2 |
| Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer | Galera Therapeutics, Inc. | Phase 2 |
Clinical Trial Summary for GC4419
Top disease conditions for GC4419
Top clinical trial sponsors for GC4419
US Patents for GC4419
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| GC4419 | Start Trial | Methods for treatment of diseases | GALERA LABS, LLC (Creve Coeur, MS) | Start Trial |
| GC4419 | Start Trial | Methods for treatment of diseases | Galera Labs, LLC (Creve Coeur, MO) | Start Trial |
| GC4419 | Start Trial | Methods for treatment of diseases | GALERA LABS, LLC (Creve Coeur, MO) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for GC4419
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| GC4419 | Australia | AU2012316397 | 2031-09-26 | Start Trial |
| GC4419 | Australia | AU2016247160 | 2031-09-26 | Start Trial |
| GC4419 | Australia | AU2019201392 | 2031-09-26 | Start Trial |
| GC4419 | Australia | AU2020244613 | 2031-09-26 | Start Trial |
| GC4419 | Canada | CA2849456 | 2031-09-26 | Start Trial |
| GC4419 | China | CN103906756 | 2031-09-26 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
